The recent operational consolidation of KBI Biopharma, Inc. and Selexis SA brings a streamlined approach to support customers in rapidly accelerating drug development and manufacturing.
We caught up with Tim Lowery, President at JSR Life Sciences, as well as J.D. Mowery, CEO at KBI Biopharma, Tony Fraij, COO at KBI Biopharma, and Sigma Mostafa, CSO at KBI Biopharma, on the floor of BIO International 2023 this past June.
Hear directly from the executive team as they discuss the operational consolidation of KBI and Selexis and how this streamlined structure enhances operational efficiencies and accelerates innovation for global biopharma customers.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com
